Wall Street Zen Downgrades Cellectis (NASDAQ:CLLS) to Sell

Cellectis (NASDAQ:CLLS - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Thursday.

Separately, Barclays reduced their price target on Cellectis from $5.00 to $4.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th.

Cellectis Trading Up 0.3%

Shares of NASDAQ:CLLS traded up $0.01 on Thursday, reaching $1.53. 6,779 shares of the company traded hands, compared to its average volume of 141,894. Cellectis has a 52 week low of $1.10 and a 52 week high of $2.95. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The business's 50-day simple moving average is $1.40 and its 200 day simple moving average is $1.58. The stock has a market capitalization of $84.77 million, a P/E ratio of -1.17 and a beta of 3.11.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The firm had revenue of $12.03 million during the quarter, compared to the consensus estimate of $12.71 million. As a group, equities analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. OLD Mission Capital LLC bought a new stake in Cellectis in the 1st quarter worth approximately $31,000. Wells Fargo & Company MN grew its holdings in shares of Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 12,500 shares in the last quarter. Acadian Asset Management LLC increased its position in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 26,461 shares during the last quarter. Millennium Management LLC purchased a new stake in Cellectis during the fourth quarter valued at $962,000. Finally, B Group Inc. purchased a new stake in Cellectis during the fourth quarter valued at $5,547,000. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.